IDEAS home Printed from https://ideas.repec.org/a/eee/csdana/v111y2017icp183-202.html
   My bibliography  Save this article

Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials

Author

Listed:
  • Alam, M. Iftakhar
  • Bogacka, Barbara
  • Coad, D. Stephen

Abstract

A new statistical method is introduced for dose finding in phase IB/IIA trials, which, along with efficacy and toxicity as endpoints, also considers pharmacokinetic information in the dose-selection procedure. Following the assignment of a current best dose to a cohort of patients, the concentration of a drug in the blood is measured at the locally D-optimal time points. The dose–response outcomes are also observed for each patient. Based on the updated information, a new dose is selected for the next cohort so that the estimated probability of efficacy is maximum, subject to the condition that the estimated probability of toxicity is not more than a chosen constant. Another condition for the dose selection is related to the total exposure of the drug in the body, expressed by the area under the concentration curve over time, so that the curative purpose is likely to be achieved in the population without overdosing. Simultaneously to the maximisation of the estimated probability of efficacy, the mean area under the concentration curve for a chosen dose is not allowed to be more than a target value taking into account its inter-patient variability. The purpose is to investigate the gain in efficiency of using pharmacokinetic measures in the dose escalation. The proposed method is found to identify the optimal dose accurately without exposing many patients to toxic doses.

Suggested Citation

  • Alam, M. Iftakhar & Bogacka, Barbara & Coad, D. Stephen, 2017. "Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials," Computational Statistics & Data Analysis, Elsevier, vol. 111(C), pages 183-202.
    • Handle: RePEc:eee:csdana:v:111:y:2017:i:c:p:183-202
    DOI: 10.1016/j.csda.2017.02.009
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0167947317300294
    Download Restriction: Full text for ScienceDirect subscribers only.
    File URL: https://libkey.io/10.1016/j.csda.2017.02.009?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Peter F. Thall & John D. Cook, 2004. "Dose-Finding Based on Efficacy–Toxicity Trade-Offs," Biometrics, The International Biometric Society, vol. 60(3), pages 684-693, September.
    2. Peter F. Thall & Hoang Q. Nguyen & Elihu H. Estey, 2008. "Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates," Biometrics, The International Biometric Society, vol. 64(4), pages 1126-1136, December.
    3. Yinghui Zhou & John Whitehead & Pasi Korhonen & Mika Mustonen, 2008. "Implementation of a Bayesian Design in a Dose-Escalation Study of an Experimental Agent in Healthy Volunteers," Biometrics, The International Biometric Society, vol. 64(1), pages 299-308, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    2. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    3. Yifei Zhang & Sha Cao & Chi Zhang & Ick Hoon Jin & Yong Zang, 2021. "A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes," Biometrics, The International Biometric Society, vol. 77(3), pages 796-808, September.
    4. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    5. Beibei Guo & Rui Zhang, 2018. "Photographic Capture-Recapture for Free-Roaming Dog Population Estimation: Is It Possible to Optimize the Dog Photo-Identification?," Biostatistics and Biometrics Open Access Journal, Juniper Publishers Inc., vol. 5(3), pages 88-90, February.
    6. Sergei Leonov & Bahjat Qaqish, 2020. "Correlated endpoints: simulation, modeling, and extreme correlations," Statistical Papers, Springer, vol. 61(2), pages 741-766, April.
    7. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    8. Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.
    9. Xinyang Huang & Jin Xu, 2020. "Estimating individualized treatment rules with risk constraint," Biometrics, The International Biometric Society, vol. 76(4), pages 1310-1318, December.
    10. Laura Deldossi & Silvia Angela Osmetti & Chiara Tommasi, 2019. "Optimal design to discriminate between rival copula models for a bivariate binary response," TEST: An Official Journal of the Spanish Society of Statistics and Operations Research, Springer;Sociedad de Estadística e Investigación Operativa, vol. 28(1), pages 147-165, March.
    11. Beibei Guo & Ying Yuan, 2017. "Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents," Journal of the American Statistical Association, Taylor & Francis Journals, vol. 112(518), pages 508-520, April.
    12. Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
    13. Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
    14. Yuxi Tao & Junlin Liu & Zhihui Li & Jinguan Lin & Tao Lu & Fangrong Yan, 2013. "Dose-Finding Based on Bivariate Efficacy-Toxicity Outcome Using Archimedean Copula," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-6, November.
    15. Shenghua Fan & Bee Leng Lee & Ying Lu, 2020. "A Curve-Free Bayesian Decision-Theoretic Design for Phase Ia/Ib Trials Considering Both Safety and Efficacy Outcomes," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 12(2), pages 146-166, July.
    16. Guosheng Yin & Yisheng Li & Yuan Ji, 2006. "Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios," Biometrics, The International Biometric Society, vol. 62(3), pages 777-787, September.
    17. Jay Bartroff & Tze Leung Lai, 2011. "Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs," Biometrics, The International Biometric Society, vol. 67(2), pages 596-603, June.
    18. Peter F. Thall & Hoang Q. Nguyen & Elihu H. Estey, 2008. "Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates," Biometrics, The International Biometric Society, vol. 64(4), pages 1126-1136, December.
    19. Christophe Le Tourneau & Hui K Gan & Albiruni R A Razak & Xavier Paoletti, 2012. "Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents," PLOS ONE, Public Library of Science, vol. 7(12), pages 1-3, December.
    20. Peter F. Thall & Hoang Q. Nguyen & Thomas M. Braun & Muzaffar H. Qazilbash, 2013. "Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes," Biometrics, The International Biometric Society, vol. 69(3), pages 673-682, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:csdana:v:111:y:2017:i:c:p:183-202. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/csda .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.